West Pharmaceutical Services, Inc. (WST) Securities Class Action Lawsuit Update [May 30, 2025]

Introduction to West Pharmaceutical Services, Inc. Lawsuit

A securities fraud class action lawsuit has been filed against West Pharmaceutical Services, Inc.  on behalf of investors who purchased West Pharmaceutical common stock between February 16, 2023, and February 12, 2025 (the “Class Period”). 

The West Pharma lawsuit alleges West and some of its executives violated federal securities laws by making materially false and misleading statements about its business operations and prospects, concealing mounting financial risks tied to contract manufacturing headwinds, continuous glucose monitoring contracts, and high margin HVP portfolio challenges.

Case Details

Caption: New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., et al. 

Case No.: 2:25-cv-02285 

Jurisdiction: United States District Court for the Eastern District of Pennsylvania 

Filed on: May 5, 2025  

Company Profile 

West Pharmaceutical Services, Inc.  is a medical supplies company specializing in drug packaging, containment solutions, and delivery devices for the generic drug industries. It has two primary business segments: Proprietary Products and Contract Manufacturing. 

West produces next-generation medical devices, including West’s SmartDose device.  West claimed SmartDose was a high margin growth product before experiencing margin pressures due to operational inefficiencies.

Class Period 

February 16, 2023 through February 12, 2025. 

Investors who acquired West Pharmaceutical common stock during the Class Period may be eligible to join the securities class action lawsuit against West Pharmaceutical Services.

Allegations 

The filed complaint alleges that West Pharmaceutical Services, Inc. made materially false and misleading statements regarding its operational performance, demand visibility, and strategic positioning throughout the Class Period. Specifically, Defendants' positive statements regarding customer demand and product performance failed to reflect significant and ongoing destocking across its high margin HVP portfolio.

Throughout the Class Period (February 16, 2023 – February 12, 2025), West Pharmaceutical attributed financial struggles to temporary COVID-related product destocking, while assuring investors that the company had strong visibility into inventory levels and future demand. However, the lawsuit alleges that these statements were materially false, concealing operational challenges and deterioration in West’s business.

Despite these emerging challenges, the Company’s Q1 2023 Form 10-Q, filed in May 2023, continued to assert, West Pharmaceutical’s current CEO Eric M. Green emphasized strong visibility into customer demand, suggesting that the company was positioned for future growth. However, as early as Q1 2023, West's financial filings began to reflect increasing strain, with contract manufacturing headwinds and unexpected revenue declines. The company continued attributing headwinds to short-term industry trends but failed to acknowledge the deeper financial risks that were materializing.

By Q3 2024, West reported additional declines and reassured investors that conditions were stabilizing. However, the filed complaint alleges that, despite claiming strong visibility, West was concealing the ongoing destocking of its high margin HVP portfolio and internal uncertainties surrounding its contract manufacturing headwinds. In particular, West Pharmaceutical’s exit from continuous glucose monitoring contracts with two major CGM customers signaled deeper challenges. These customers had begun transitioning to in-house manufacturing of next-generation devices, removing a significant revenue stream from West’s portfolio.

Additionally, the lawsuit contends that West’s SmartDose device, initially presented as a high margin growth product, became highly dilutive to West Pharmaceutical’s profit margins due to operational inefficiencies. The company acknowledged in its February 13, 2025 earnings guidance that West Pharmaceutical’s SmartDose device was expected to be margin dilutive in 2025, prompting further concerns from investors. 

 As a result of these undisclosed issues, West’s public statements about its demand visibility, revenue stability, and margin expansion lacked a reasonable basis and were materially misleading.  The filed complaint alleges West and certain of its executives violated federal securities laws, such as the Securities Exchange Act, by withholding from investors pertinent information or making materially false or misleading public statements related to West’s demand, revenue, margins, and business performance.  

The Truth Emerges 

The truth about West Pharmaceutical’s deteriorating margins and weakening customer demand came to light through a series of damaging disclosures across three key dates. 
 
On February 15, 2024, West issued a deeply disappointing earnings report. The Company attributed its financial struggles to ongoing destocking, confirming that the company’s high margin HVP portfolio had suffered from contract manufacturing headwinds and unexpected operational inefficiencies. Investors, who had relied on prior statements claiming strong visibility into business conditions, reacted sharply.
 
Then, on July 25, 2024, West issued revised full-year guidance, revealing further troubles. The Company admitted not only to ongoing destocking but that destocking was far more severe than expected. The report revealed customer demand was down across the board, particularly in biologics and generic -- two areas where high-value products were heavily concentrated. 
 
Finally, on February 13, 2025, West stunned investors by slashing its 2025 revenue and earnings outlook. The Company admitted it had lost two major continuous glucose monitoring (CGM) clients and revealed that SmartDose -- once positioned as West's key money-maker -- was actually highly dilutive to the Company's profit margins. This troubling news underscored severity of West's operational challenges and further shook investor confidence in the Company’s leadership capabilities. 

Market Reaction 

Each of these disclosures triggered steep declines in West’s stock price: 
- February 15, 2024: Shares dropped $57.49 (14%), closing at $350.70.   
- July 25, 2024: Shares fell another $46.61 (14.4%), closing at $277.16.   
- February 13, 2025: The Company’s stock plunged $123.17 (38%) to close at $199.11.   
 
Analysts expressed surprise and disappointment regarding West's lackluster guidance and lack of foresight. William Blair analysts described West’s forecast as a “very disappointing guide,” highlighting that SmartDose performance had worsened and expressing surprise at the unannounced loss of major CGM contracts—contracts that accounted for over 20% of West’s CM revenue in 2024.   

Next Steps 

• Submissions for lead plaintiff are due July 7, 2025.  

• The Court will issue its order for lead-plaintiff and counsel in the weeks after submissions are due. 

• The Court will then consider a motion for class certification.   

• The Court will later consider a motion to dismiss. 

To learn if you are eligible for recovery under the West securities class action lawsuit, visit the case submission page here.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.